PL3497132T3 - Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu - Google Patents
Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabuInfo
- Publication number
- PL3497132T3 PL3497132T3 PL17768863T PL17768863T PL3497132T3 PL 3497132 T3 PL3497132 T3 PL 3497132T3 PL 17768863 T PL17768863 T PL 17768863T PL 17768863 T PL17768863 T PL 17768863T PL 3497132 T3 PL3497132 T3 PL 3497132T3
- Authority
- PL
- Poland
- Prior art keywords
- ofatumumab
- regimens
- methods
- multiple sclerosis
- treating multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| EP17768863.7A EP3497132B1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3497132T3 true PL3497132T3 (pl) | 2020-11-30 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17768863T PL3497132T3 (pl) | 2016-08-15 | 2017-08-11 | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
| PL20180938.1T PL3733712T3 (pl) | 2016-08-15 | 2017-08-11 | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20180938.1T PL3733712T3 (pl) | 2016-08-15 | 2017-08-11 | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
Country Status (24)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190038914A (ko) * | 2016-08-15 | 2019-04-09 | 노파르티스 아게 | 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법 |
| CN118436777A (zh) | 2019-09-11 | 2024-08-06 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| CA3152192A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| KR20220166827A (ko) * | 2020-04-09 | 2022-12-19 | 노파르티스 아게 | 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙 |
| JP2024514126A (ja) * | 2021-04-14 | 2024-03-28 | ノバルティス アーゲー | アジア人患者における多発性硬化症を治療するためのオファツムマブ |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP1272518A2 (en) | 2000-03-30 | 2003-01-08 | Amgen, Inc. | Cd20/ige-receptor like molecules and uses thereof |
| EP1311530A4 (en) | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| CN103709250B (zh) | 2002-10-17 | 2016-08-10 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| WO2012096924A1 (en) | 2011-01-10 | 2012-07-19 | Glaxo Group Limited | Novel uses |
| KR102102111B1 (ko) * | 2012-02-08 | 2020-04-20 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄｉｍ 결합 단백질 및 이의 용도 |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| JP6348492B2 (ja) * | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物 |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| KR20190038914A (ko) | 2016-08-15 | 2019-04-09 | 노파르티스 아게 | 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법 |
| CA3152192A1 (en) | 2019-09-11 | 2021-03-18 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| CN118436777A (zh) | 2019-09-11 | 2024-08-06 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| KR20220166827A (ko) | 2020-04-09 | 2022-12-19 | 노파르티스 아게 | 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙 |
| JP2024514126A (ja) | 2021-04-14 | 2024-03-28 | ノバルティス アーゲー | アジア人患者における多発性硬化症を治療するためのオファツムマブ |
| KR20240046200A (ko) | 2021-08-16 | 2024-04-08 | 노파르티스 아게 | 소아 ms 치료를 위한 오파투무맙 |
-
2017
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262416A (en) | Materials and methods for the treatment of hemoglobin diseases | |
| SG11201706766WA (en) | Materials and methods for treatment of hemoglobinopathies | |
| IL274865A (en) | Treatment methods with asparaginase | |
| IL276890A (en) | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab | |
| IL323354A (en) | Methods for treating pulmonary hypertension with combinations of relinfag and other substances | |
| IL252296A0 (en) | Methods for treating multiple sclerosis | |
| IL265359A (en) | Modified Oligonucleotides and Methods of Use | |
| IL256207B (en) | Methods for treating multiple sclerosis | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201804380B (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| LT3661510T (lt) | Elgesio pakitimų gydymo būdai | |
| SG11201805729SA (en) | Therapeutic compositions and methods for treating hepatitis b | |
| IL259096A (en) | Peptides and methods of treating endometriosis using the same | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| IL265387A (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| GB201817198D0 (en) | Treatment ported sub and method of use | |
| ZA201906319B (en) | Methods of treating depression | |
| GB201516544D0 (en) | Spraying device and method of using same | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| SG11201710199PA (en) | Methods of treating multiple sclerosis | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| IL283365A (en) | Treatment methods for follicular lymphoma |